Literature DB >> 9560877

[Fetal pathology in Fabry's disease and mucopolysaccharidosis type I].

M Elleder1, H Poupĕtová, V Kozich.   

Abstract

Fetal Fabry disease (defect of alfa galactosidase) and mucopolysaccharidosis I (defect of alfa iduronidase, family with IH phenotype) were diagnosed by biochemistry in two risk gravidities subsequently interrupted according to mother's demand. Fetus with Fabry disease (gestation age 19 weeks) had rudimentary storage in kidney and myenteric plexuses cells, cardiocytes were normal. Biopsy of chorionic villi showed a bit more conspicuous storage in single trophoblastic elements. Much more striking storage was observed in MPS I (gestational age 14-15 weeks) especially in liver (hepatocytes and sinus cells), spleen (sinus endothelial cells and pulp macrophages) and fibroblasts of skin and placenta. Skin peripheral nerves and cerebral cortical gangliocytes did not show any lysosomal storage. Different manifestation of storage in fetal age may reflex the speed of lysosomal storage development in both lysosomal enzymopathies.

Entities:  

Mesh:

Year:  1998        PMID: 9560877

Source DB:  PubMed          Journal:  Cesk Patol        ISSN: 1210-7875


  13 in total

1.  Fabry disease and nephrogenic diabetes insipidus.

Authors:  Philip Wornell; Sarah Dyack; John Crocker; Weiming Yu; Philip Acott
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

Review 2.  Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.

Authors:  Marianne Rohrbach; Joe T R Clarke
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry.

Authors:  Christoph Wanner; João P Oliveira; Alberto Ortiz; Michael Mauer; Dominique P Germain; Gabor E Linthorst; Andreas L Serra; László Maródi; Renzo Mignani; Bruno Cianciaruso; Bojan Vujkovac; Roberta Lemay; Dana Beitner-Johnson; Stephen Waldek; David G Warnock
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-02       Impact factor: 8.237

4.  Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.

Authors:  Behzad Najafian; Einar Svarstad; Leif Bostad; Marie-Claire Gubler; Camilla Tøndel; Chester Whitley; Michael Mauer
Journal:  Kidney Int       Date:  2010-12-15       Impact factor: 10.612

5.  Manifestations of Fabry disease in placental tissue.

Authors:  A C Vedder; A Strijland; M A vd Bergh Weerman; S Florquin; J M F G Aerts; C E M Hollak
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

Review 6.  Assessment of renal pathology and dysfunction in children with Fabry disease.

Authors:  Uma Ramaswami; Behzad Najafian; Arrigo Schieppati; Michael Mauer; Daniel G Bichet
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

Review 7.  Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis.

Authors:  Claire Zar-Kessler; Amel Karaa; Katherine Bustin Sims; Virginia Clarke; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2016-04-15       Impact factor: 4.409

Review 8.  Unusual renal presentation of Fabry disease in a female patient.

Authors:  Cataldo Abaterusso; Vincenzo De Biase; Alessandro Salviati; Antonia Fabris; Deborah Millardi; Paola Tomei; Patrizia Bernich; Antonio Lupo; Giovanni Gambaro
Journal:  Nat Rev Nephrol       Date:  2009-04-28       Impact factor: 28.314

9.  Fabry disease in children and the effects of enzyme replacement treatment.

Authors:  Guillem Pintos-Morell; Michael Beck
Journal:  Eur J Pediatr       Date:  2009-02-26       Impact factor: 3.183

10.  Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

Authors:  Fernando C Fervenza; Roser Torra; David G Warnock
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.